

Bertram L Kasiske

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9483886/publications.pdf>

Version: 2024-02-01

96
papers

10,306
citations

61984

43
h-index

37204

96
g-index

101
all docs

101
docs citations

101
times ranked

11872
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence, Clinical Correlates, and Outcomes of Pulmonary Hypertension After Kidney Transplantation: Analysis of Linked US Registry and Medicare Billing Claims. <i>Transplantation</i> , 2022, 106, 666-675.	1.0	3
2	The Effect of Acuity Circles on Deceased Donor Transplant and Offer Rates Across Model for End-Stage Liver Disease Scores and Exception Statuses. <i>Liver Transplantation</i> , 2022, 28, 363-375.	2.4	31
3	Five Years With the American Journal of Kidney Diseases on the Road to Evidence-Based Medicine. <i>American Journal of Kidney Diseases</i> , 2022, 79, 1-2.	1.9	3
4	Associations of Lack of Insurance and Other Sociodemographic Traits With Follow-up After Living Kidney Donation. <i>American Journal of Kidney Diseases</i> , 2022, 80, 683-685.	1.9	2
5	Cancer risk in living kidney donors. <i>American Journal of Transplantation</i> , 2022, 22, 2006-2015.	4.7	6
6	iHFTA and chronic active T cell-mediated rejection: A tale of 2 (DeKAF) cohorts. <i>American Journal of Transplantation</i> , 2021, 21, 1866-1877.	4.7	16
7	Mortality among solid organ waitlist candidates during COVID-19 in the United States. <i>American Journal of Transplantation</i> , 2021, 21, 2262-2268.	4.7	24
8	Outcomes of Living Kidney Donor Candidate Evaluations in the Living Donor Collective Pilot Registry. <i>Transplantation Direct</i> , 2021, 7, e689.	1.6	16
9	Incidence, risk factors, and long-term outcomes associated with antibody-mediated rejection – The long-term Deterioration of Kidney Allograft Function (DeKAF) prospective cohort study. <i>Clinical Transplantation</i> , 2021, 35, e14337.	1.6	6
10	Procurement Biopsies in Kidney Transplantation: More Information May Not Lead to Better Decisions. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1835-1837.	6.1	13
11	A New Panel-Estimated GFR, Including \hat{I}^2 -Microglobulin and \hat{I}^2 -Trace Protein and Not Including Race, Developed in a Diverse Population. <i>American Journal of Kidney Diseases</i> , 2021, 77, 673-683.e1.	1.9	47
12	Incidence, risk factors, treatment, and consequences of antibody-mediated kidney transplant rejection: A systematic review. <i>Clinical Transplantation</i> , 2021, 35, e14320.	1.6	32
13	Survival implications of prescription opioid and benzodiazepine use in lung transplant recipients: Analysis of linked transplant registry and pharmacy fill records. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 513-524.	0.6	7
14	Outcomes of living liver donor candidate evaluations in the Living Donor Collective pilot registry. <i>Clinical Transplantation</i> , 2021, 35, e14394.	1.6	6
15	A prospective controlled study of metabolic and physiologic effects of kidney donation suggests that donors retain stable kidney function over the first nine years. <i>Kidney International</i> , 2020, 98, 168-175.	5.2	34
16	Survey of US Living Kidney Donation and Transplantation Practices in the COVID-19 Era. <i>Kidney International Reports</i> , 2020, 5, 1894-1905.	0.8	54
17	Continuous distribution as an organ allocation framework. <i>Current Opinion in Organ Transplantation</i> , 2020, 25, 115-121.	1.6	23
18	Outcome implications of benzodiazepine and opioid co-prescription in kidney transplant recipients. <i>Clinical Transplantation</i> , 2020, 34, e14005.	1.6	6

#	ARTICLE	IF	CITATIONS
19	Prescription patterns of opioids and non-steroidal anti-inflammatory drugs in the first year after living kidney donation: An analysis of U.S. Registry and Pharmacy fill records. <i>Clinical Transplantation</i> , 2020, 34, e14000.	1.6	4
20	Economic impacts of alternative kidney transplant immunosuppression: A national cohort study. <i>Clinical Transplantation</i> , 2020, 34, e13813.	1.6	2
21	The economic burden of kidney graft failure in the United States. <i>American Journal of Transplantation</i> , 2020, 20, 1323-1333.	4.7	18
22	Tool to Aid Patients in Selecting a Liver Transplant Center. <i>Liver Transplantation</i> , 2020, 26, 337-348.	2.4	8
23	Impacts of center and clinical factors in antihypertensive medication use after kidney transplantation. <i>Clinical Transplantation</i> , 2020, 34, e13803.	1.6	2
24	Summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. <i>Transplantation</i> , 2020, 104, 708-714.	1.0	73
25	Inflammation in areas of fibrosis: The DeKAF prospective cohort. <i>American Journal of Transplantation</i> , 2020, 20, 2509-2521.	4.7	18
26	Application of the 2017 KDIGO Guideline for the Evaluation and Care of Living Kidney Donors to Clinical Practice. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 896-905.	4.5	19
27	KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. <i>Transplantation</i> , 2020, 104, S11-S103.	1.0	306
28	Impact of Functional Status on Outcomes of Simultaneous Pancreas-kidney Transplantation: Risks and Opportunities for Patient Benefit. <i>Transplantation Direct</i> , 2020, 6, e599.	1.6	15
29	Prescription opioid use before and after heart transplant: Associations with posttransplant outcomes. <i>American Journal of Transplantation</i> , 2019, 19, 3405-3414.	4.7	12
30	Associations of obesity with antidiabetic medication use after living kidney donation: An analysis of linked national registry and pharmacy fill records. <i>Clinical Transplantation</i> , 2019, 33, e13696.	1.6	13
31	Lifetime benefits of early detection and treatment of diabetic kidney disease. <i>PLoS ONE</i> , 2019, 14, e0217487.	2.5	20
32	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 1304-1317.	5.2	232
33	Cannabis Dependence or Abuse in Kidney Transplantation: Implications for Posttransplant Outcomes. <i>Transplantation</i> , 2019, 103, 2373-2382.	1.0	36
34	Molecular phenotype of kidney transplant indication biopsies with inflammation in scarred areas. <i>American Journal of Transplantation</i> , 2019, 19, 1356-1370.	4.7	41
35	Long-term follow-up of the DeKAF cross-sectional cohort study. <i>American Journal of Transplantation</i> , 2019, 19, 1432-1443.	4.7	20
36	An economic assessment of contemporary kidney transplant practice. <i>American Journal of Transplantation</i> , 2018, 18, 1168-1176.	4.7	250

#	ARTICLE	IF	CITATIONS
37	Transplant recipients are vulnerable to coverage denial under Medicare Part D. American Journal of Transplantation, 2018, 18, 1502-1509.	4.7	18
38	Offer acceptance practices and geographic variability in allocation model for end-stage liver disease at transplant. Liver Transplantation, 2018, 24, 478-487.	2.4	17
39	Center practice drives variation in choice of US kidney transplant induction therapy: a retrospective analysis of contemporary practice. Transplant International, 2018, 31, 198-211.	1.6	46
40	Temporal trends, center-level variation, and the impact of prevalent state obesity rates on acceptance of obese living kidney donors. American Journal of Transplantation, 2018, 18, 642-649.	4.7	23
41	Late graft failure after kidney transplantation as the consequence of late versus early events. American Journal of Transplantation, 2018, 18, 1158-1167.	4.7	39
42	Antidepressant medication use before and after kidney transplant: implications for outcomes - a retrospective study. Transplant International, 2018, 31, 20-31.	1.6	12
43	Center-driven and Clinically Driven Variation in US Liver Transplant Maintenance Immunosuppression Therapy: A National Practice Patterns Analysis. Transplantation Direct, 2018, 4, e364.	1.6	16
44	Organ distribution without geographic boundaries: A possible framework for organ allocation. American Journal of Transplantation, 2018, 18, 2635-2640.	4.7	56
45	Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management. Kidney International, 2018, 94, 663-673.	5.2	72
46	Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet, The, 2017, 390, 1888-1917.	13.7	662
47	Survival implications of opioid use before and after liver transplantation. Liver Transplantation, 2017, 23, 305-314.	2.4	63
48	Closing the gap between evidence and practice in chronic kidney disease. Kidney International Supplements, 2017, 7, 114-121.	14.2	14
49	The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease. Kidney International Supplements, 2017, 7, 130-137.	14.2	8
50	What patients and members of their support networks ask about transplant program data. Clinical Transplantation, 2017, 31, e13125.	1.6	19
51	KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. Transplantation, 2017, 101, S7-S105.	1.0	308
52	Abnormalities in biomarkers of mineral and bone metabolism in kidney donors. Kidney International, 2016, 90, 861-868.	5.2	20
53	Impact of increased time at the highest urgency category on heart transplant outcomes for candidates with ventricular assist devices. Journal of Heart and Lung Transplantation, 2016, 35, 326-334.	0.6	10
54	The Authors Reply. Kidney International, 2016, 90, 708.	5.2	0

#	ARTICLE	IF	CITATIONS
55	Statins for hemodialysis patients with diabetes? Long-term follow-up endorses the original conclusions of the 4D Study. <i>Kidney International</i> , 2016, 89, 1189-1191.	5.2	6
56	Recommendations for kidney disease guideline updating: a report by the KDIGO Methods Committee. <i>Kidney International</i> , 2016, 89, 753-760.	5.2	13
57	Allocating Deceased Donor Kidneys to Candidates with High Panelâ€“Reactive Antibodies. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 505-511.	4.5	49
58	Gout After Living Kidney Donation: A Matched Cohort Study. <i>American Journal of Kidney Diseases</i> , 2015, 65, 925-932.	1.9	45
59	Delayed hepatocellular carcinoma model for endâ€“stage liver disease exception score improves disparity in access to liver transplant in the United States. <i>Hepatology</i> , 2015, 61, 1643-1650.	7.3	107
60	Long-term medical risks to the living kidney donor. <i>Nature Reviews Nephrology</i> , 2015, 11, 411-419.	9.6	63
61	Melanoma Risk and Survival among Organ Transplant Recipients. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2657-2665.	0.7	108
62	The Authors Reply:. <i>Kidney International</i> , 2015, 87, 863-864.	5.2	0
63	Cardiovascular risk assessment in kidney transplantation. <i>Kidney International</i> , 2015, 87, 527-534.	5.2	70
64	Kidney Disease: Improving Global Outcomes--an update. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 763-769.	0.7	20
65	New National Allocation Policy for Deceased Donor Kidneys in the United States and Possible Effect on Patient Outcomes. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1842-1848.	6.1	338
66	The Role of Procurement Biopsies in Acceptance Decisions for Kidneys Retrieved for Transplant. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 562-571.	4.5	85
67	The reninâ€“aldosterone axis in kidney transplant recipients and its association with allograft function and structure. <i>Kidney International</i> , 2014, 85, 404-415.	5.2	17
68	Potential Effects of Reclassifying CKD as a Coronary Heart Disease Risk Equivalent in the US Population. <i>American Journal of Kidney Diseases</i> , 2014, 63, 753-760.	1.9	13
69	The kidney and lipids: preface. <i>Clinical and Experimental Nephrology</i> , 2014, 18, 180-184.	1.6	0
70	Polycystic Kidney Disease and Cancer after Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2335-2341.	6.1	59
71	Outcomes After Living Kidney Donation: What We Still Need to Knowâ€“andâ€“Why. <i>American Journal of Kidney Diseases</i> , 2014, 64, 335-337.	1.9	13
72	A Prospective Controlled Study of Kidney Donors: Baseline and 6-Month Follow-up. <i>American Journal of Kidney Diseases</i> , 2013, 62, 577-586.	1.9	323

#	ARTICLE	IF	CITATIONS
73	The Management of Dyslipidemia in CKD: New Analyses of an Expanding Dataset. American Journal of Kidney Diseases, 2013, 61, 371-374.	1.9	8
74	Scientific Registry of Transplant Recipients: Collecting, analyzing, and reporting data on transplantation in the United States. Transplantation Reviews, 2013, 27, 50-56.	2.9	246
75	A Prospective, Multinational Pharmacoepidemiological Study of Clinical Conversion to Sirolimus Immunosuppression after Renal Transplantation. Journal of Transplantation, 2012, 2012, 1-16.	0.5	6
76	Evidence and Outcomes in CKD. American Journal of Kidney Diseases, 2012, 59, 492-494.	1.9	3
77	Spectrum of Cancer Risk Among US Solid Organ Transplant Recipients. JAMA - Journal of the American Medical Association, 2011, 306, 1891.	7.4	1,176
78	Design Considerations and Feasibility for a Clinical Trial to Examine Coronary Screening Before Kidney Transplantation (COST). American Journal of Kidney Diseases, 2011, 57, 908-916.	1.9	30
79	A Simple Tool to Predict Outcomes After Kidney Transplant. American Journal of Kidney Diseases, 2010, 56, 947-960.	1.9	75
80	KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney International, 2010, 77, 299-311.	5.2	675
81	Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A US Physician Perspective. American Journal of Kidney Diseases, 2007, 50, 354-357.	1.9	3
82	Acute Myocardial Infarction and Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2006, 17, 900-907.	6.1	165
83	Risk-Stratified Screening for Ischemic Heart Disease in Kidney Transplant Candidates. Transplantation, 2005, 80, 815-820.	1.0	48
84	Long-Term Deterioration of Kidney Allograft Function. American Journal of Transplantation, 2005, 5, 1405-1414.	4.7	107
85	Cancer after Kidney Transplantation in the United States. American Journal of Transplantation, 2004, 4, 905-913.	4.7	924
86	Hypertension after kidney transplantation. American Journal of Kidney Diseases, 2004, 43, 1071-1081.	1.9	356
87	A thirty percent chronic decline in inverse serum creatinine is an excellent predictor of late renal allograft failure. American Journal of Kidney Diseases, 2002, 39, 762-768.	1.9	65
88	Ischemic heart disease after renal transplantation. Kidney International, 2002, 61, 356-369.	5.2	32
89	Matching Older Kidneys with Older Patients Does Not Improve Allograft Survival. Journal of the American Society of Nephrology: JASN, 2002, 13, 1067-1072.	6.1	80
90	The evaluation of renal transplantation candidates: clinical practice guidelines. American Journal of Transplantation, 2001, 1 Suppl 2, 3-95.	4.7	130

#	ARTICLE	IF	CITATIONS
91	A Meta-Analysis of Immunosuppression Withdrawal Trials in Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2000, 11, 1910-1917.	6.1	356
92	Cigarette Smoking in Renal Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2000, 11, 753-759.	6.1	182
93	Explained and Unexplained Ischemic Heart Disease Risk after Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2000, 11, 1735-1743.	6.1	440
94	Glomerular hemodynamic and structural alterations in experimental diabetes mellitus. FASEB Journal, 1988, 2, 2339-2347.	0.5	135
95	Toward continuous improvement of Scientific Registry of Transplant Recipients performance reporting: Advances following 2012 consensus conference and future consensus building for 2022 consensus conference. Clinical Transplantation, 0, , .	1.6	2
96	Transplant program evaluations in the middle of the COVID-19 pandemic. American Journal of Transplantation, 0, , .	4.7	0